By Alexei Oreskovic SAN FRANCISCO, April 4 (Reuters) - The personal data gathering abilities of Google, Facebook and other tech companies has sparked growing unease among Americans, with a majority worried that Internet companies ar...
LOS ANGELES (AP) — Microsoft Corp., which has skewered rival Google Inc. for going through customer emails to deliver ads, acknowledged Thursday it had searched emails in a blogger's Hotmail account to track down who was leaking company secrets...
A new study of high-performing pharma companies reveals science-based innovation strategies and patient-outcome-based commercial models are now the key drivers of growth. Anne O’Riordan reports.
A select group of high performing pharma companies are significantly breaking away from the pack in terms of high performance in profitability, growth, future value, consistency and longevity, according to recent biopharmaceutical high performance business research. These high performing pharma companies are able to achieve this by focusing on innovation-driven growth strategies that are substantiated by patient- outcome-focused commercial models.
Richard Meyer's insight:
The analysis identified four key take-aways:
1. There is clear evidence of continued recovery in industry performance. The research shows a continued recovery in the first ten months of 2013 with enterprise value (1) up 14 per cent and reaching 11 per cent above the pre-recession peak of 2006. However, there is a wide range of performance between individual companies.
2. Some companies are breaking away from the pack through science-based innovation strategies: Several high performing companies have faster average growth forecasts than their peer group, largely driven by recent and upcoming product launches, based upon scientific innovations versus truly diversified strategies.
3. High performers are putting science back into life sciences: Many of the high performers are outperforming the averages for the rest of the peer group on three key forward-looking metrics — a higher replacement revenue ratio forecast, higher five-year forecast revenue growth average and a higher proportion of forecast growth from new product when compared with averages for the rest of the peer group.
4. High performers are leading the industry's pivot to the patient: High performers have been able to bring new products to market with a clear articulated view on how the drugs improve patient outcomes and are consequently able to carve out a unique place in today’s price and value-conscious health market.
Good morning. Microsoft Corp. Chief Executive Satya Nadella is starting to reshape the team helping him lead his company. The elevation to chief strategy officer of Mark Penn, a man more widely known as a political polling consultant than technology maven, could be a reflection of Mr. Nadella's focus on customers. Venture capitalist Doug Burgum, who managed Mr. Nadella for nearly seven years, says the new Microsoft leader has a different perspective on Microsoft's markets than other insiders because he worked in areas Microsoft didn't dominate. “His customer empathy is very high, because he’s worked for some [Microsoft] groups that faced strong competition and that forces you into a spot where you’ve got to really listen to the customer,” Mr. Burgum tells CIO Journal.
Washington, Dec. 10 (ANI): Two of the biggest tech companies, and rivals, Apple and Microsoft might not only work together in the near future but also merge in the next 5-10 years, a market analyst has predicted.